Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy?

Journal of Nephrology

Volumn 23, Issue 2, 2010, Pages 156-163

  Ponticelli, Claudio ^a   Passerini, Patrizia ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Glomerulonephritis prognosis; Glomerulonephritis treatment; Membranous nephropathy; Nephrotic syndrome

Indexed keywords

ALPHA 1 MICROGLOBULIN; CHLORAMBUCIL; CREATINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; STEROID;

AGE DISTRIBUTION; CARDIOVASCULAR RISK; CAUCASIAN; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ETHNIC DIFFERENCE; HISTOPATHOLOGY; HUMAN; JAPANESE; KIDNEY FUNCTION; LIFE EXPECTANCY; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PREDICTION; PREVALENCE; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STEROID THERAPY; SURVIVAL RATE; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGE FACTORS; BIOLOGICAL MARKERS; CHILD; DISEASE PROGRESSION; ETHNIC GROUPS; EVIDENCE-BASED MEDICINE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE; NEPHROTIC SYNDROME; PATIENT SELECTION; PROTEINURIA; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77749242553     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001;59:1983-1994.
2. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23:324-332.
3. Ponticelli C, Passerini P. Membranous nephropathy. In: Ponticelli C and Glassock RJ, eds. Treatment of primary glomerulonephritis. Vol. 1. Oxford: Oxford Medical Publications; 1996:146-185.
4. Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400-1407.
5. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25:862-875.
6. Takei T, Aoki A, Eguchi A, et al. Effects of steroid therapy on membranous nephropathy. Nippon Jinzo Gakkai Shi. 2008;50:597-601.
7. Tang S, Chan TM, Cheng IK, Lai KN. Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients. QJM. 1999;92:401-406.
8. Makker SP. Treatment of membranous nephropathy in children. Semin Nephrol. 2003;23:379-385.
9. Chen A, Frank R, Vento S, et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol. 2007;8:11.
10. Valentini RP, Mattoo TK, Kapur G, Imam A. Membranous glomerulonephritis: treatment response and outcome in children. Pediatr Nephrol. 2009;24:301-308.
11. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16:271-282.
12. Callis L, Nieto J, Vila A, Rende J. Chlorambucil treatment in minimal lesion nephrotic syndrome: a reappraisal of its gonadal toxicity. J Pediatr. 1980;97:653-656.
13. Ponticelli C. Membranous nephropathy. J Nephrol. 2007;20:268-287.
14. Cameron JS. Membranous nephropathy and its treatment. Nephrol Dial Transplant. 1992;(7 Suppl 1):72-79.
15. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23:324-332.
16. Zent R, Nagai R, Kaplan DC. Idiopathic membranous nephropathy in the elderly. Am J Kidney Dis. 1997;29:200-206.
17. Passerini P, Como G, Viganò E, et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant. 1993;8:1321-1325.
18. Hopper J, Trew PA, Biava CG. Membranous nephropathy: its relative benignity in women. Nephron. 1981;29:18-24.
19. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, Troyanov S; the Genes, Gender and Glomerulonephritis Group. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant. 2008;23:2247-2253.
20. Davison AM, Cameron JS, Kerr DN, Ogg CS, Wilkinson RW. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol. 1984;22:61-67.
21. Murphy BF, Fairley KF, Kincaid-Smith PS. Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. Clin Nephrol. 1988;30:175-181.
22. Donadio JV Jr, Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988;33:708-715.
23. Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol. 1994;41:127-134.
24. Marx BE, Marx M. Prediction in idiopathic membranous nephropathy. Kidney Int. 1999;56:666-673.
25. Bazzi C, Petrini C, Rizza V, et al. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis. 2001;38:240-248.
26. Pei Y, Cattran DC, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992;42:960-966.
27. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 1997;51:901-907.
28. du Buf-Vereijken PW, Feith GW, Hollander D, et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. QJM. 2004;97:353-360.
29. Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996;27:765-775.
30. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-1456.
31. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44:638-642.
32. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int. 1994;45:578-585.
33. Imai H. Medical decision-making in membranous nephropathy: how to use limited clinical research evidence in patient management. Clin Exp Nephrol. 2005;9:206-211.
34. Piccoli A, Pillon L, Passerini P, Ponticelli C. Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis. Kidney Int. 1994;45:1193-1202.
35. Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant. 1989;4:525-529.
36. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66:1199-1205.
37. Ponticelli C, Passerini P, Altieri P, Locatelli F, Pappalettera M. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant. 1992;7 Suppl 1:85-90.
38. Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet. 1988;2:869-872.
39. Jindal K, West M, Bear R, Goldstein M. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous nephropathy and impaired renal function. Am J Kidney Dis. 1992;19:61-67.
40. Torres A, Dominguez-Gil B, Carreño A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61:219-227.
41. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46:1012-1029.
42. Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1984;310:946-950.
43. Fuiano G, Stanziale P, Balletta M, et al. Effectiveness of steroid therapy in different stages of membranous nephropathy. Nephrol Dial Transplant. 1989;4:1022-1029.
44. Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, ed. Pathology annual. New York: Appleton-Century-Crofts; 1968:145-186.
45. Wehrmann M, Bohle A, Bogenschütz O, et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis: an analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol. 1989;31:67-76.
46. Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;320:8-13.
47. Troyanov S, Roasio L, Pandes M, Herzenberg AM, Cattran DC. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006;69:1641-1648.
48. Wu Q, Jinde K, Nishina M, et al. Analysis of prognostic predictors in idiopathic membranous nephropathy. Am J Kidney Dis. 2001;37:380-387.
49. Alexopoulos E, Leontsini M, Papadimitriou M. Relationship between interstitial infiltrates and steroid responsiveness in membranous nephropathy. Nephrol Dial Transplant. 1994;9:623-629.
50. Oda T, Yoshizawa N, Oshima S, et al. [Monoclonal antibody analysis of glomerular, tubulo-interstitial infiltrating immune cells in various glomerulonephritis] [article in Japanese]. Nippon Jinzo Gakkai Shi. 1990;32:631-641.
51. Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41:38-48.
52. Heeringa SF, Branten AJ, Deegens JK, Steenbergen E, Wetzels JF. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropa thy. Nephrol Dial Transplant. 2007;22:2201-2207.
53. Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous nephropathy. Kidney Int. 1992;41:428-434.
54. Yoshimoto K, Yokoyama H, Wada T, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int. 2004;65:148-153.
55. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48:1600-1604.
56. Branten AJ, du Buf-Vereijken PW, Klasen IS, et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol. 2005;16:169-174.
57. Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 2007;71:504-513.
58. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18:2221-2228.
59. Dede F, Ayili D, Sahiner S. Effective treatment administration of cyclophosphamide in membranous nephropathy. J Nephrol. 2008;21:560-565.
60. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007;72:1429-1447.
61. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71:924-930.
62. Arikan H, Koc M, Cakalagaoglu F, et al. Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol. 2008;21:713-721.
63. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007;50:248-256.
64. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999;56:1534-1543.
65. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47:233-240.
66. Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol. 2006;1:738-748.
67. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73:117-125.